- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06513156
Kontinuum der Versorgung von Krankenhauspatienten mit Opioidkonsumstörung und infektiösen Komplikationen durch Drogenkonsum (CHOICE-STAR)
Das Kontinuum der Versorgung von Krankenhauspatienten mit Opioidkonsumstörung und infektiösen Komplikationen des Drogenkonsums – NavSTAR, Treatment as Usual, Sucht-/ID-integrierte Klinik zur Verhinderung infektionsbedingter Rückübernahmen
This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes.
(1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and medication for OUD (MOUD) treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers.
The study will recruit patients during hospitalization for an infection due to injecting opioids or stimulants at four hospital systems (five hospitals) and randomly assign approximately 304 inpatients in 1:1 ratio to IC vs TAU.
Participants will be followed for 12 months.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Rachel Silk
- Telefonnummer: 301-326-7652
- E-Mail: rsilk@ihv.umaryland.edu
Studienorte
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20052
- Rekrutierung
- George Washington University
-
Unterermittler:
- Irene Kuo, MD
-
Kontakt:
- Jill Catalanotti, MD
- E-Mail: jcatalanotti@mfa.gwu.edu
-
Hauptermittler:
- Jill Catalanotti, MD
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University
-
Hauptermittler:
- Joseph Carpenter, MD
-
Kontakt:
- Joseph Carpenter, MD
- E-Mail: joseph.edward.carpenter@emory.edu
-
Unterermittler:
- Alina Steck, MD
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland Baltimore
-
Unterermittler:
- Edward Traver, MD
-
Hauptermittler:
- Elana Rosenthal, MD
-
Unterermittler:
- Sarah Kattakuzhy, MD
-
Kontakt:
- Rachel Silk
- Telefonnummer: 3013267652
- E-Mail: rsilk@ihv.umaryland.edu
-
-
West Virginia
-
Morgantown, West Virginia, Vereinigte Staaten, 26506
- Rekrutierung
- West Virginia University
-
Kontakt:
- Rebecca Reece, MD
- E-Mail: rreece@hsc.wvu.edu
-
Hauptermittler:
- Rebecca Reece, MD
-
Unterermittler:
- Clinton Cooper, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥ 18 years
- Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
- Injection opioid or stimulant use in past 90 days - per patient self-report
- Active suspected or confirmed qualifying infection (see list) at time of admission.
Qualifying infections:
- Non-vertebral osteomyelitis
- Vertebral osteomyelitis or discitis
- Epidural, subdural, or extradural abscess
- Intracranial or intraspinal abscess
- Native joint septic arthritis
- Prosthetic joint septic arthritis
- Blood stream infection (bacterial or fungal)
- Native valve Endocarditis
- Prosthetic valve endocarditis
- Cardiac Implantable electronic device infection
- Infectious pseudoaneurysm and aneurysm
- Infected vascular graft
- Septic venous thrombosis
- Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
- Infected skin ulcer
- Orthopedic hardware infection
- Muscle abscess/myositis
- Central nervous system infection (bacterial or fungal)
- Bacterial or fungal ophthalmologic infection
- Other abscess
- Pulmonary septic emboli
- Other acute bacterial or fungal infection deemed appropriate by site study team
Exclusion Criteria:
-
1. Infection due to a cause other than injection drug use, per determination of a site PI.
2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.
3. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Treatment As Usual
Will receive treatment for infection and opioid or stimulant use disorder per the usual care at each hospital |
|
|
Experimental: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
The Integrated ID/SUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating SUD, resolving the sentinel infection, treating existing ID complications of OUD/stimulants (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and SUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and SUD providers. |
Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Infection Rehospitalization
Zeitfenster: 6 months after discharge for index hospitalization
|
New hospitalization due to infection following discharge for index hospitalization |
6 months after discharge for index hospitalization
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to first infection related readmission
Zeitfenster: 12 months after discharge for index hospitalization
|
Time to first infection related readmission |
12 months after discharge for index hospitalization
|
|
Reason for infection related readmission
Zeitfenster: 12 months after discharge for index hospitalization
|
Reason for infection related readmission (persistent index infection, new IDU associated infection, other infection) |
12 months after discharge for index hospitalization
|
|
Hospital services utilization
Zeitfenster: 12 months after discharge for index hospitalization
|
ED visits (Binary, count, time to first ED visit, cause) and Readmission, all cause (binary, count, time to first readmission, cause) |
12 months after discharge for index hospitalization
|
|
Mortality
Zeitfenster: 12 months after discharge for index hospitalization
|
Death (Binary, time to death, cause of death) |
12 months after discharge for index hospitalization
|
|
Index infection
Zeitfenster: 3 months after discharge for index hospitalization
|
Completion of antibiotics (binary, reason for incomplete antibiotics); Resolution of index infection (binary) Skilled Nursing Facility (SNF) Admitted to SNF (binary) Discharge type from SNF (planned, PDD, dead, transfer) |
3 months after discharge for index hospitalization
|
|
Other Infections
Zeitfenster: 12 months after discharge for index hospitalization
|
HCV Active HCV (binary) Clinical evaluation (binary) DAA prescribed (binary) DAA initiated (binary) SVR achieved (binary) HIV Diagnosis status (binary) HIV VL undetectable (binary) ART Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) PrEP Eligible (CDC Criteria, binary, indication) Offered by healthcare provider (binary) Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) |
12 months after discharge for index hospitalization
|
|
Skin and soft tissue wounds
Zeitfenster: 12 months after discharge for index hospitalization
|
Present (binary) Number (count) Per wound Size Location on body Duration (continuous) |
12 months after discharge for index hospitalization
|
|
New infections not requiring hospitalization
Zeitfenster: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Outpatient linkage and retention
Zeitfenster: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for Opioid Use (MOUD)
Zeitfenster: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for stimulant use (MStUD)
Zeitfenster: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Substance Use-Opioid
Zeitfenster: 12 months after discharge for index hospitalization
|
Ongoing opioid (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Substance Use - Stimulant
Zeitfenster: 12 months after discharge for index hospitalization
|
Ongoing stimulant use (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Cost Effectiveness
Zeitfenster: 12 months after discharge for index hospitalization
|
• ICER for quality adjusted life years (QALYs); opioid-free years (OfYs); and infection-free years (IfYs) gained |
12 months after discharge for index hospitalization
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Elana Rosenthal, MD, University of Maryland, Baltimore
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HP-00111318
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .